Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TSPT's Cash to Debt is ranked higher than
99% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. TSPT: No Debt )
TSPT' s 10-Year Cash to Debt Range
Min: 3.32   Max: No Debt
Current: No Debt

Equity to Asset 0.94
TSPT's Equity to Asset is ranked higher than
96% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. TSPT: 0.94 )
TSPT' s 10-Year Equity to Asset Range
Min: -4.61   Max: 0.98
Current: 0.94

-4.61
0.98
Interest Coverage No Debt
TSPT's Interest Coverage is ranked higher than
88% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TSPT: No Debt )
TSPT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 4.72
M-Score: -5.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1041.69
TSPT's Operating margin (%) is ranked higher than
56% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. TSPT: -1041.69 )
TSPT' s 10-Year Operating margin (%) Range
Min: -44400   Max: -19.11
Current: -1041.69

-44400
-19.11
Net-margin (%) -1046.55
TSPT's Net-margin (%) is ranked higher than
55% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. TSPT: -1046.55 )
TSPT' s 10-Year Net-margin (%) Range
Min: -42508.93   Max: -19.7
Current: -1046.55

-42508.93
-19.7
ROE (%) -24.12
TSPT's ROE (%) is ranked higher than
73% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. TSPT: -24.12 )
TSPT' s 10-Year ROE (%) Range
Min: -582.11   Max: -5.99
Current: -24.12

-582.11
-5.99
ROA (%) -23.38
TSPT's ROA (%) is ranked higher than
72% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. TSPT: -23.38 )
TSPT' s 10-Year ROA (%) Range
Min: -74.75   Max: -5.43
Current: -23.38

-74.75
-5.43
ROC (Joel Greenblatt) (%) -1763.59
TSPT's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. TSPT: -1763.59 )
TSPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17632.86   Max: -311.78
Current: -1763.59

-17632.86
-311.78
Revenue Growth (%) -54.10
TSPT's Revenue Growth (%) is ranked higher than
57% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. TSPT: -54.10 )
TSPT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 53
Current: -54.1

0
53
EBITDA Growth (%) 30.70
TSPT's EBITDA Growth (%) is ranked higher than
95% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. TSPT: 30.70 )
TSPT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 95.1
Current: 30.7

0
95.1
EPS Growth (%) 28.40
TSPT's EPS Growth (%) is ranked higher than
93% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. TSPT: 28.40 )
TSPT' s 10-Year EPS Growth (%) Range
Min: -82   Max: 95
Current: 28.4

-82
95
» TSPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TSPT Guru Trades in Q3 2013

Jim Simons 108,200 sh (+31.79%)
Whitney Tilson Sold Out
» More
Q4 2013

TSPT Guru Trades in Q4 2013

Jim Simons 75,100 sh (-30.59%)
» More
Q1 2014

TSPT Guru Trades in Q1 2014

Jim Simons 89,000 sh (+18.51%)
» More
Q2 2014

TSPT Guru Trades in Q2 2014

Jim Simons 227,846 sh (+156.01%)
» More
» Details

Insider Trades

Latest Guru Trades with TSPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.92
TSPT's P/B is ranked higher than
98% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. TSPT: 0.92 )
TSPT' s 10-Year P/B Range
Min: 0.17   Max: 8.51
Current: 0.92

0.17
8.51
P/S 25.63
TSPT's P/S is ranked higher than
70% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. TSPT: 25.63 )
TSPT' s 10-Year P/S Range
Min: 0.21   Max: 2193.33
Current: 25.63

0.21
2193.33
EV-to-EBIT 1.88
TSPT's EV-to-EBIT is ranked higher than
99% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TSPT: 1.88 )
TSPT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 1.88

Current Ratio 17.79
TSPT's Current Ratio is ranked higher than
96% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. TSPT: 17.79 )
TSPT' s 10-Year Current Ratio Range
Min: 1.74   Max: 60.13
Current: 17.79

1.74
60.13
Quick Ratio 17.79
TSPT's Quick Ratio is ranked higher than
96% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. TSPT: 17.79 )
TSPT' s 10-Year Quick Ratio Range
Min: 1.74   Max: 60.13
Current: 17.79

1.74
60.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.95
TSPT's Price/Net Cash is ranked higher than
99% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. TSPT: 0.95 )
TSPT' s 10-Year Price/Net Cash Range
Min: 0.44   Max: 5.39
Current: 0.95

0.44
5.39
Price/Net Current Asset Value 0.95
TSPT's Price/Net Current Asset Value is ranked higher than
99% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. TSPT: 0.95 )
TSPT' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 11.88
Current: 0.95

0.44
11.88
Price/Tangible Book 0.93
TSPT's Price/Tangible Book is ranked higher than
99% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. TSPT: 0.93 )
TSPT' s 10-Year Price/Tangible Book Range
Min: 0.43   Max: 6.46
Current: 0.93

0.43
6.46
Price/Median PS Value 3.87
TSPT's Price/Median PS Value is ranked higher than
67% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. TSPT: 3.87 )
TSPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 249.5
Current: 3.87

0.08
249.5
Earnings Yield (Greenblatt) 53.20
TSPT's Earnings Yield (Greenblatt) is ranked higher than
91% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. TSPT: 53.20 )
TSPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: 53.2

Forward Rate of Return (Yacktman) -73.13
TSPT's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. TSPT: -73.13 )
TSPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -723.3   Max: -19.7
Current: -73.13

-723.3
-19.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:N4C1.Germany
Transcept Pharmaceuticals, Inc. was incorporated in Delaware in 2001. Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder.
» More Articles for TSPT

Headlines

Articles On GuruFocus.com
Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 
Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 14 2009 
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 14 2009 
Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 22 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 16 2014
TRANSCEPT PHARMACEUTICALS INC Financials Aug 19 2014
Q2 2014 Transcept Pharmaceuticals Inc. Earnings Release - Time Not Supplied Aug 11 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Jul 03 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 01 2014
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO Jul 01 2014
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement Jul 01 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 16 2014
Transcept Pharmaceuticals board declares special dividend of $1.33 per share May 14 2014
Transcept Declares Special Cash Dividend Of $25 Million May 14 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 05 2014
Transcept Pharmaceuticals Reports First Quarter 2014 Financial Results May 05 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 14 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 13 2014
Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Mar 13 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal... Mar 05 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 14 2014
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit Jan 13 2014
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit Jan 13 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 02 2014
TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 20 2013
Transcept Final Voting Results for Special Meeting of Stockholders Provide Strong Support for... Dec 19 2013
Transcept Pharmaceuticals Statement on the Withdrawal of the Unsolicited Indication of Interest from... Dec 17 2013
Transcept Pharmaceuticals Announces That Largest Stockholder, Roumell Asset Management, Declares... Dec 17 2013
Transcept Pharmaceuticals Announces that Glass Lewis & Co. Recommends "AGAINST" All Proposals... Dec 13 2013
Transcept Pharmaceuticals Announces that ISS Proxy Advisory Services Recommends "AGAINST" All... Dec 11 2013
Transcept Pharmaceuticals Provides Update to Key Initiatives Being Undertaken to Increase... Dec 04 2013
Transcept Pharmaceuticals Announces Plans to Reduce Expenses Through a Reduction in Force and a... Nov 13 2013
Transcept Pharmaceuticals Reports Third Quarter Financial Results Nov 07 2013
Transcept Pharmaceuticals to Report Third Quarter 2013 Financial Results and Host Conference Call on... Nov 04 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK